The private company’s China-based partner is Shenzhen Kangtai Biological Products Co Ltd (SZKT), one of the largest vaccine manufacturers in China.
Calling the approval from MOH timely, YTB chief executive officer and executive director Datuk Wira Boo Kuang Loon said that it came after the company’s proactive efforts over the past four months to ensure all regulatory and safety requirements are met for them to obtain the approval for Phase 3 clinical trial.
“With our collaboration, we…